I-Nystatin dihydrate CAS: 1400-61-9 Nystatin A1> 85%;naziphi na ezinye iikhompawundi
| Inombolo Yekhathalogu | XD90352 |
| Igama lemveliso | I-Nystatin dihydrate |
| CAS | 1400-61-9 |
| Ifomula yeemolekyuli | C47H75NO17 · 2H2O |
| Ubunzima beMolekyuli | 962.10 |
| Iinkcukacha zokuGcina | -15 ukuya -20 °C |
| IKhowudi yoMrhumo eHarmonized | 29419000 |
Ukucaciswa kweMveliso
| Ukuqukumbela | Ihambelana ne-Ph.Eur.9.7 |
| Pseudomonas aeruginosa | Ukungabikho |
| pH | 6.0-8.0 (3% isisombululo samanzi) |
| Isivavanyi | I-Nystatin A1> 85%;naziphi na ezinye iikhompawundi <4% |
| Ilahleko ekomisweni | <5.0% |
| Imbonakalo | Umgubo omthubi okanye omdaka ngebala |
| Uthuthu olufakwe emanzini | <3.5% |
| Uvavanyo lwesazisi D | Iyahambelana (UV) |
| TAMC | <1000cfu/g |
| I-TYMC | <100cfu/g |
| Staphylococcus Aureus | Ukungabikho |
| I-Residual Solvent Methanol | <3000ppm |
| I-Mesityloxide | <500ppm |
| Intsalela yokunyibilika | <5000ppm |
| Uvavanyo lokuchongwa (UV) A | iyafana nereferensi |
| Absorbance A305 | >0.6 |
| ibhaktiriya ekwaziyo ukunyamezela igram-negative (E.coli + Salmonella sp.) | Ukungabikho |
| Iintlobo zeClostridia | Ukungabikho |
| Izinyibilikisi ezishiyekileyo (1-butanol) | <1000ppm |
| Ubunyulu;Uvavanyo lweMicrobial | NLT>4400 IU/mg kwisiseko esomileyo |
Ukumisela izinto eziguquguqukayo zeklinikhi ukwahlula i-aspergillosis ye-pulmonary (IPA) kwi-colonization kwizigulane ezine-pneumopathies ezingapheliyo kunye nenkcubeko efanelekileyo ye-Aspergillus spp.kwiisampulu zokuphefumla.Uphononongo lweqela elibuyela emva kuqukwa nezigulane ezinezodwa zokuphefumla ze-Aspergillus spp.ngexesha le-10 leminyaka.I-IPA yavavanywa ngokwemigaqo ye-Bulpa.Izinto eziguquguqukayo zeklinikhi zaqokelelwa kwaye uhlalutyo oluninzi lwenziwa.Izigulane ezingamashumi asibhozo anesithathu kunye ne-Aspergillus spp.ukusuka kwiisampulu zokuphefumula zabandakanywa;I-68.7% (n = 57) yezigulane zine-chronic obstructive pulmonary disease, i-18% (n = 15) i-pulmonary fibrosis kunye ne-13.3% (n = 11) i-asthma ye-bronchial.Izigulane ezingamashumi amabini anesibini (26.6%) zine-IPA.Ukusetyenziswa kwe-fluconazole (OKANYE 4.49; CI 95% 1.5-13.4; P = .007), ukungaphumeleli kokuphefumula okukhulu (OKANYE 4.64; CI 95% 1.46-14.72; P = .009) kunye nexesha lokulaliswa esibhedlele (OKANYE 1.05; CI 95% I-1.01-1.1; P = .006) yayidibene ne-IPA.Ukusetyenziswa kwangaphambili kwe-fluconazole, ukungaphumeleli kokuphefumula okukhulu kunye nexesha lokulaliswa esibhedlele lidibaniswa ne-IPA kwizigulane ezine-pneumopathies ezingapheliyo kunye nokuhlukaniswa kokuphefumula kwe-Aspergillus spp.Copyright © 2012 Elsevier España, SL Onke amalungelo igciniwe
